Mortality in a large tuberculosis treatment trial: Modifiable and non-modifiable risk factors

International Journal of Tuberculosis and Lung Disease

Volumn 10, Issue 5, 2006, Pages 542-549

  Sterling, Timothy R ^a   Zhao, Z ^b   Khan, A ^b   Chaisson, R E ^c   Schluger, N ^d   Mangura, B ^e   Weiner, M ^f   Vernon, A ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Columbia University College of Physicians and Surgeons ^*  (United States)

^e RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^f SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

HIV; Malignancy; Mortality; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; AUTOPSY; CAUSE OF DEATH; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH CERTIFICATE; DRUG TOLERANCE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT FAILURE; UNEMPLOYMENT;

ADULT; AMERICAS; ANTITUBERCULAR AGENTS; CANADA; CAUSE OF DEATH; CHI-SQUARE DISTRIBUTION; DIRECTLY OBSERVED THERAPY; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MULTICENTER STUDIES; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 33646342793     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Centers for Disease Control and Prevention. Trends in tuberculosis morbidity - United States, 1992-2002. MMWR 2003; 52: 217-222.
2. Fielder J F, Chaulk C P, Dalvi M, Gachuhi R, Comstock G W, Sterling T R. A high tuberculosis case-fatality rate in a setting of effective tuberculosis control: implications for acceptable treatment success rates. Int J Tuberc Lung Dis 2002; 6: 1114-1117.
3. de Meer G, van Geuns H A. Rising case fatality of bacteriologically proven pulmonary tuberculosis in The Netherlands. Tubercle Lung Dis 1992; 73: 83-86.
4. Humphries M J, Byfield S P, Darbyshire J H, et al. Deaths occurring in newly notified patients with pulmonary tuberculosis in England and Wales. Br J Dis Chest 1984; 78: 149-158.
5. Churchyard G J, Kleinschmidt I, Corbett E L, Murray J, Smit J, DeCock K M. Factors associated with an increased case-fatality rate in HIV-infected and non-infected South African gold miners with pulmonary tuberculosis. Int J Tuberc Lung Dis 2000; 4: 705-712.
6. Accinelli R A, Hernandez K, Alvarez L M, et al. Risk factors for failing, dying, and defaulting among TB patients treated with DOTS. Am J Respir Crit Care Med 2002; 165: A438.
7. Oursler K K, Moore R D, Bishai W R, Harrington S M, Pope D S, Chaisson R E. Survival of patients with pulmonary tuberculosis: clinical and molecular epidemiologic factors. Clin Infect Dis 2002; 34: 752-759.
8. Tuberculosis Trials Consortium. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomized clinical trial. Lancet 2002; 360: 528-534.
9. Vernon A, Burman W, Senator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet 1999; 353: 1843-1847.
10. Kent P T, Kubica G P. Public health mycobacteriology: a guide for the level III laboratory. Atlanta, GA: Centers for Disease Control and Prevention, US Public Health Service, 1985.
11. 1983 metropolitan height and weight tables. Stat Bull Metrop Life Found 1983; 64: 3-9.
12. Centers for Disease Control and Prevention/National Center for Health Statistics/National Vital Statistics System. Deaths: Final data for 1997. National Vital Statistics Report 1998; 47 (19): 99-1120.
13. Kircher T, Nelson J, Burdo H. The autopsy as a measure of accuracy of the death certificate. N Engl J Med 1985; 313: 1263-1269.
14. Washko R M, Frieden T R. Tuberculosis surveillance using death certificate data, New York City, 1992. Public Health Rep 1996; 111: 251-255.
15. Heldal E, Naalsund A, Kongerud J, Tverdal A, Boe J. Deaths from active tuberculosis: can we rely on notification and mortality figures? Tubercle Lung Dis 1996; 77: 215-219.
16. American Thoracic Society, Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161: S221-S247.
17. Dewan P K, Arguin P M, Kiryanova H, et al. Risk factors for death during tuberculosis treatment in Orel, Russia. Int J Tuberc Lung Dis 2004; 8: 598-602.
18. Pablos-Mendez A, Sterling T R, Frieden T R. The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis. JAMA 1996; 276: 1223-1228.
19. Cayla J A, Caminero J A, Rev R, Lara N, Valles X, Galdos-Tanguis H. Current status of treatment completion and fatality among tuberculosis patients in Spain. Int J Tuberc Lung Dis 2004; 8: 458-464.
20. Borgdorff M W, Veen J, Kalisvaart N A, Nagelkerke N. Mortality among tuberculosis patients in The Netherlands in the period 1993-1995. Eur Respir J 1998; 11: 816-820.
21. Rao V K, Iademarco E P, Fraser V J, Kollef M H. The impact of comorbidity on mortality following in-hospital diagnosis of tuberculosis. Chest 1998; 114: 1244-1252.
22. Hansel N N, Merriman B, Haponik E F, Diette G B. Hospitalizations for tuberculosis in the United States in 2000: predictors of in-hospital mortality. Chest 2004; 126: 1079-1086.
23. Walpola H C, Siskind V, Patel A M, Konstantinos A, Derhy P. Tuberculosis-related deaths in Queensland, Australia, 1989-1998: characteristics and risk factors. Int J Tuberc Lung Dis 2003; 7: 742-750.
24. Burman W, Benator D, Vernon A, et al. Acquired rifamycin-resistance with twice-weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care Med 2006; 173: 350-356.
25. Dheda K, Lampe F C, Johnson M A, Lipman M C. Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis 2004; 190: 1670-1676.
26. Lucas G M, Cheever L W, Chaisson R E, Moore R D. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr 2001; 27: 251-259.
27. Mathur P, Sacks L, Auten G, Sall R, Levy C, Gordin F. Delayed diagnosis of pulmonary tuberculosis in city hospitals. Arch Intern Med 1994; 154: 306-310.
28. Harries A D, Hargreaves N J, Gausi F, Kwanjana J H, Salaniponi F M. High early death rate in tuberculosis patients in Malawi. Int J Tuberc Lung Dis 2001; 5: 1000-1005.
29. Alwood K, Keruly J, Moore-Rice K, Stanton D L, Chaulk C P, Chaisson R E. Effectiveness of supervised, intermittent therapy for tuberculosis in HIV-infected patients. AIDS 1994; 8: 1103-1108.
30. Jasmer R M, Seaman C B, Gonzalez L C, Kawamura L M, Osmond D H, Daley C L. Tuberculosis treatment outcomes: directly observed therapy compared with self-administered therapy. Am J Respir Crit Care Med 2004; 170: 561-566.